NCT07073170View on ClinicalTrials.gov

A Study of LY3549492 in Chinese Participants With Type 2 Diabetes Mellitus

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Type 2 Diabetes
Interventions
DRUG

LY3549492

Administered orally

DRUG

Placebo

Administered orally

Trial Locations (3)

100009

Peking University First Hospital, Dongcheng District

100033

Peking University People's Hospital, Beijing

610041

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY